JP6483714B2 - 噴霧乾燥製剤 - Google Patents

噴霧乾燥製剤 Download PDF

Info

Publication number
JP6483714B2
JP6483714B2 JP2016547977A JP2016547977A JP6483714B2 JP 6483714 B2 JP6483714 B2 JP 6483714B2 JP 2016547977 A JP2016547977 A JP 2016547977A JP 2016547977 A JP2016547977 A JP 2016547977A JP 6483714 B2 JP6483714 B2 JP 6483714B2
Authority
JP
Japan
Prior art keywords
substituted
groups
unsubstituted
group
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016547977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534153A (ja
JP2016534153A5 (https=
Inventor
ローレンス エス． ジスマン，
ローレンス エス． ジスマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016534153A publication Critical patent/JP2016534153A/ja
Publication of JP2016534153A5 publication Critical patent/JP2016534153A5/ja
Application granted granted Critical
Publication of JP6483714B2 publication Critical patent/JP6483714B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016547977A 2013-10-11 2014-10-10 噴霧乾燥製剤 Active JP6483714B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361889887P 2013-10-11 2013-10-11
US61/889,887 2013-10-11
PCT/US2014/060039 WO2015054574A1 (en) 2013-10-11 2014-10-10 Spray dry formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019024568A Division JP6823095B2 (ja) 2013-10-11 2019-02-14 噴霧乾燥製剤

Publications (3)

Publication Number Publication Date
JP2016534153A JP2016534153A (ja) 2016-11-04
JP2016534153A5 JP2016534153A5 (https=) 2017-11-16
JP6483714B2 true JP6483714B2 (ja) 2019-03-13

Family

ID=52813663

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016547977A Active JP6483714B2 (ja) 2013-10-11 2014-10-10 噴霧乾燥製剤
JP2019024568A Active JP6823095B2 (ja) 2013-10-11 2019-02-14 噴霧乾燥製剤
JP2021001507A Pending JP2021063119A (ja) 2013-10-11 2021-01-07 噴霧乾燥製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019024568A Active JP6823095B2 (ja) 2013-10-11 2019-02-14 噴霧乾燥製剤
JP2021001507A Pending JP2021063119A (ja) 2013-10-11 2021-01-07 噴霧乾燥製剤

Country Status (8)

Country Link
US (2) US9925184B2 (https=)
EP (1) EP3054937B1 (https=)
JP (3) JP6483714B2 (https=)
CN (2) CN111743901B (https=)
AU (3) AU2014331796B2 (https=)
CA (1) CA2926793C (https=)
ES (1) ES2959419T3 (https=)
WO (1) WO2015054574A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
HK1218720A1 (zh) 2013-04-30 2017-03-10 欧缇托匹克公司 干粉制剂及使用方法
LT3060041T (lt) 2013-10-25 2021-03-25 Insmed Incorporated Prostaciklino junginiai
JP6866043B2 (ja) 2014-11-18 2021-04-28 インスメッド インコーポレイテッド トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
WO2017132601A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry powder inhaler
US10898494B2 (en) * 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
KR20250037589A (ko) * 2016-06-17 2025-03-17 유나이티드 쎄러퓨틱스 코포레이션 향상된 효능을 가진 세포외 소포
RU2763525C2 (ru) * 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102681843B1 (ko) 2017-09-22 2024-07-05 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2019157337A1 (en) * 2018-02-08 2019-08-15 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
JP7090941B2 (ja) * 2018-10-02 2022-06-27 学校法人 名城大学 吸入粉末剤、その評価方法及びその用途
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
EP3968963A4 (en) 2019-05-16 2023-02-01 Aerovate Therapeutics, Inc. IMATINIB FORMULATIONS, THEIR PREPARATION AND USES
US11691879B2 (en) 2020-01-11 2023-07-04 Third Pole, Inc. Systems and methods for nitric oxide generation with humidity control
JPWO2021201258A1 (https=) * 2020-04-01 2021-10-07
CA3199091A1 (en) * 2020-11-23 2022-05-27 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
CN117157282A (zh) * 2021-05-07 2023-12-01 Gb002股份有限公司 N-{3-[(1s)-1-{[6-(3,4-二甲氧基苯基)吡嗪-2-基]氨基}乙基]苯基}-5-甲基吡啶-3-甲酰胺的结晶形式及相关产品和方法
JP2025526021A (ja) 2022-08-10 2025-08-07 ジービー００２，インコーポレイティド 肺動脈性高血圧症（ｐａｈ）を治療するためのチロシンキナーゼ阻害剤とアクチビン２型受容体アンタゴニストの併用療法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118401A (en) 1977-10-19 1978-10-03 American Hoechst Corporation Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor
JPS5488231A (en) 1977-12-22 1979-07-13 Sumitomo Chem Co Ltd 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5648369A (en) 1991-11-20 1997-07-15 University Of Kentucky Research Foundation Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists
CZ61098A3 (cs) 1995-08-30 1998-06-17 Bayer Aktiengesellschaft Amidy kyseliny acylaminosalicylové jako prostředky pro potírání škůdců, způsob jejich výroby a meziprodukty pro jejich výrobu
JPH09268169A (ja) 1996-04-01 1997-10-14 Otsuka Chem Co Ltd サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
AU763041B2 (en) * 1999-08-25 2003-07-10 Alkermes, Inc. Modulation of release from dry powder formulations
US6586433B2 (en) 1999-09-23 2003-07-01 Pharmacia Corporation Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
HRP20020349A2 (en) 1999-10-19 2004-02-29 Merck & Co Inc Tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778417B2 (en) 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
DE60323642D1 (de) 2002-05-23 2008-10-30 Cohen Ben Z Medizinisch genaues pumpsystem
NZ537156A (en) 2002-05-23 2007-06-29 Cytopia Pty Ltd Kinase inhibitors
DE60317198T2 (de) 2002-05-23 2008-12-04 Cytopia Research Pty. Ltd., Richmond Proteinkinaseinhibitoren
DK1522314T3 (da) 2002-06-26 2014-05-26 Ono Pharmaceutical Co Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse
US20060063782A1 (en) 2002-07-03 2006-03-23 Murray Christopher W 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
KR20050029209A (ko) 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. 화합물, 조성물 및 이의 사용방법
US20060154936A1 (en) 2002-10-25 2006-07-13 Lasky Joseph A Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
FR2858459B1 (fr) 2003-08-01 2006-03-10 Commissariat Energie Atomique Commutateur micro-mecanique bistable, methode d'actionnement et procede de realisation correspondant
WO2005013982A1 (en) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
CN102225926A (zh) 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
BRPI0417345A (pt) 2003-12-03 2007-03-13 Cytopia Res Pty Ltd compostos inibidores de quìnase baseados em azola, composições e seus usos
CA2545422C (en) 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Tubulin inhibitors
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
WO2005114219A2 (en) 2004-05-20 2005-12-01 Wyeth Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
JP2006111553A (ja) 2004-10-13 2006-04-27 Dainippon Sumitomo Pharma Co Ltd スルホニルオキシインドール誘導体及びそれを含有する医薬組成物
WO2007054215A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl ureas for treating pulmonary hypertension
WO2007087575A2 (en) 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
WO2007124382A2 (en) * 2006-04-19 2007-11-01 Novartis Vaccines And Diagnostics, Inc. Inhaled imipenem
DK2848610T3 (da) 2006-11-15 2017-11-06 Ym Biosciences Australia Pty Hæmmere af kinaseaktivitet
EP2152688A1 (en) 2007-05-04 2010-02-17 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2148874B1 (en) 2007-05-04 2012-02-08 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
CA2697081C (en) 2007-08-22 2013-04-23 Irm Llc 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors
CA2697077C (en) 2007-08-22 2012-10-16 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
US8288402B2 (en) 2007-12-20 2012-10-16 Bayer Intellectual Property Gmbh 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
BRPI0917491A2 (pt) 2008-08-13 2015-12-01 Novartis Ag tratamento de hipertensao arterial pulmonar
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
WO2010132827A1 (en) 2009-05-15 2010-11-18 Bend Research, Inc. Low-molecular dextran for powder inhalations
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2709646A4 (en) * 2011-05-19 2015-05-13 Savara Inc DRY POWDER VANCOMYCIN COMPOSITIONS AND RELATED METHODS
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
WO2014110198A2 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Therapeutic indications of kinase inhibitors
EP3007689B1 (en) * 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors

Also Published As

Publication number Publication date
EP3054937A1 (en) 2016-08-17
JP2021063119A (ja) 2021-04-22
AU2014331796A1 (en) 2016-04-28
EP3054937A4 (en) 2017-05-03
CA2926793A1 (en) 2015-04-16
EP3054937B1 (en) 2023-07-26
CN106132403A (zh) 2016-11-16
US20160235742A1 (en) 2016-08-18
JP2019089830A (ja) 2019-06-13
AU2022203611A1 (en) 2022-06-16
AU2014331796B2 (en) 2020-05-07
JP2016534153A (ja) 2016-11-04
CA2926793C (en) 2022-11-22
WO2015054574A1 (en) 2015-04-16
CN106132403B (zh) 2020-04-28
US20180193336A1 (en) 2018-07-12
AU2020202556A1 (en) 2020-05-07
CN111743901B (zh) 2023-09-12
US9925184B2 (en) 2018-03-27
JP6823095B2 (ja) 2021-01-27
CN111743901A (zh) 2020-10-09
ES2959419T3 (es) 2024-02-26

Similar Documents

Publication Publication Date Title
JP6823095B2 (ja) 噴霧乾燥製剤
AU2023201605B2 (en) Non-selective kinase inhibitors
JP2016506417A (ja) キナーゼ阻害剤の治療指標
HK40036372B (zh) 喷雾干燥制剂
HK40036372A (en) Spray dry formulations

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160920

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190214

R150 Certificate of patent or registration of utility model

Ref document number: 6483714

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250